The company said that the new patent will expire in 2023.
RegeneRx claims that it holds patents and patent applications worldwide related to its products and holds an exclusive worldwide license from the National Institutes of Health, as well as other licenses related to Tß4.
RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4, for tissue and organ protection, repair and regeneration.
RegeneRx currently has three products in clinical development, RGN-352, RGN-259, RGN-137.